Late in her third year, an associate is handed a number. It is large, it arrives without a derivation, and the partners describe it as “what everyone paid.” She has 30 days to accept, no ability to check the arithmetic, and a strong suspicion that asking too many questions will be read as a lack of commitment. That is the standard buy-in conversation in American medicine, and it is a poor start to a 20-year relationship.
Begin with what is actually being sold, because pricing errors on both sides trace back to a misunderstanding of the object. An incoming partner is not buying the practice. She is buying a minority seat in an illiquid asset with, realistically, one future buyer—the practice itself. She receives no control, no ability to force a sale, and no way to convert the interest to cash on her own initiative. An outside acquirer pays its multiple precisely because it gets control, scale synergies, and the right to reprice the practice’s future, none of which transfers to her. Value the internal buy-in at outside-market standards and the price lands somewhere between frightening and impossible on the balance sheet of a physician in her late thirties still carrying medical school debt and a mortgage. This is why healthy practices deliberately price the internal market below what an outside sale would fetch. The deflation is not a favor. It is the accurate price of the thing being sold.
What the price is built from is a short list. Collectible accounts receivable, valued at what they will actually collect rather than at what the aging report says. Equipment and furnishings at conservative real value—accelerated depreciation writes assets to zero the year they are purchased, so net book value for equipment measures a tax election rather than anything in the building. Vaccine inventory, by physical count or one month’s vaccine expense as a proxy. And the earnings value of the enterprise, which is the part that causes every argument, because it is where goodwill lives: the panel, the brand, the systems, the staff, and the referral relationships that took two decades to assemble.
That last component explains why book value and fair market value produce such different answers. Book value prices the balance sheet, and a cash-basis pediatric balance sheet omits the receivables (often), the vaccine inventory (usually), and the entire earnings value of the enterprise (always). A book-value clause in an older agreement can therefore price a 25 percent interest near $70,000 when a defensible earnings-based method prices the same interest above $300,000. Practices have transferred hundreds of thousands of dollars from founders to associates by accident that way, and then watched the same clause turn on the founder at her own exit.
Every admission answers four questions, and the classic disputes are all cases of one of them being answered by accident.
Variable one is price methodology, and it carries the single non-negotiable rule of the entire subject: whatever methodology prices the way in prices the way out. Asymmetric methodologies are wealth transfers with a signature page. The methodology gets disclosed with a worked example to every signatory, and it names the odd assets—including, where the practice is a C corporation, any loss carry-forward, which is a six-figure tax asset that agreements routinely leave unmentioned on both sides.
Variable two is payment structure. The menu is short: a salary differential, a practice-financed note, bank financing, or equity in lieu of bonus. Each carries a different tax character, and both sides’ accountants should model it before anyone agrees. Whatever the structure, it goes into a formal promissory note with stated interest and security provisions, alongside a written schedule of what has been earned at each stage, so a mid-track departure unwinds without argument.
Variable three is timeline and track. A stated associate period of two to three years is standard, governed by objective criteria—productivity thresholds, board certification, practice citizenship, and insurability for the practice’s buyout funding—with the admission vote threshold named. The sharpest criterion gates the option on recovered investment rather than tenure: the option opens after two to three years and $150,000 to $300,000 of cumulative profit generated for the practice, with $200,000 the working floor most practices settle on. Time served is the weakest criterion available. Breaking even after 18 months is not a high enough bar for access to ownership, and nobody builds a full panel in a year. Disclose the methodology up front, too. An associate who cannot learn the price formula until year three is negotiating blind, and practices that publish the methodology recruit measurably better. Then audit the track against its own history: if the stated track is two to three years and the last three associates made partner in year five, the recruiting pitch is fiction.
Variable four is the rights the equity conveys, and it is the one everyone discovers at a letter of intent. Voting rights, immediately or after a probation of non-voting economics. Distribution participation and its formula. And sale-proceeds participation, which matters precisely because the internal price was deflated. A straight pro rata split of an eventual third-party sale hands the newest partner an outside-market windfall on equity she bought at the internal price. Agreements answer this with tenure tiering, capital-based tiering, a vesting schedule on sale participation, or the strongest form, the delta-recapture provision: new partners buy at the internal valuation, and if the practice is ever sold to a third party, the founding owners receive the difference between internal and external value. Draft it at admission, when it is a pricing conversation. Raise it at the letter of intent and it is a betrayal.
The arithmetic belongs on the table in both directions. On a $200,000 buy-in against a $50,000 annual income differential, a note at 8 percent consumes $16,000 of the first year’s differential, so the full return arrives only when the note retires, and the payback period on the principal runs about four years. State the differential from the practice’s actual books rather than a projection, and name the risks that justify a premium return—illiquidity, a single future buyer, and capital truly at risk. A candidate shown that arithmetic can compare partnership against any other use of $200,000. A candidate shown only a price can decide only whether she has the money.
The sellers owe themselves the same pass, and they skip it more often. Dilution, not discount, is the real cost of admission, and the buy-in check does not compensate for it—the newcomer’s production has to. If a mirror test fails from either chair, the answer is rarely a better payment plan.
Red flags. A buy-in price set by feel rather than by a formal methodology. Goodwill undefined, with personal and enterprise goodwill used interchangeably by people who mean different things. Installment payments with no promissory note. A partnership track described in conversation and nowhere else. And no trigger tying the buy-in price to a current valuation, so the number being paid describes a practice that no longer exists.
A buy-in without a valuation is not a negotiation. It is a guess with a signature line, and one side always regrets it.
The price builds from collectible accounts receivable valued at what they will actually collect, equipment and furnishings at conservative real value rather than net book value, vaccine inventory by physical count or one month's vaccine expense, and the earnings value of the enterprise. That last component holds goodwill: the panel, brand, systems, staff, and referral relationships.
Yes. Whatever methodology prices the way in prices the way out, and that symmetry is the single non-negotiable rule of the subject, because asymmetric methodologies are wealth transfers with a signature page. A book-value clause can price a 25 percent interest near $70,000 when a defensible earnings-based method prices the same interest above $300,000.
A stated associate period of two to three years is standard, governed by objective criteria such as productivity thresholds, board certification, practice citizenship, and insurability, with the admission vote threshold named. The sharpest criterion gates the option on recovered investment: two to three years plus $150,000 to $300,000 of cumulative profit generated, with $200,000 the working floor.
The Partnership Agreement Analyzer scores an existing agreement against the framework this series is built on — or schedule a discovery call to work through it with PMI. The full framework, with the arithmetic, lives in the textbook Pediatric Practice Management: The Fundamentals.